These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Changes in natural immunity during the course of HIV-1 infection. Brenner BG; Gryllis C; Gornitsky M; Wainberg MA Clin Exp Immunol; 1993 Aug; 93(2):142-8. PubMed ID: 7688673 [TBL] [Abstract][Full Text] [Related]
3. Diminution of inducible lymphokine-activated killer cell activity in individuals with AIDS-related disorders. Gryllis C; Wainberg MA; Gornitsky M; Brenner B AIDS; 1990 Dec; 4(12):1205-12. PubMed ID: 2088399 [TBL] [Abstract][Full Text] [Related]
4. Human lymphokine-activated killer cells are cytotoxic against cells infected with Toxoplasma gondii. Subauste CS; Dawson L; Remington JS J Exp Med; 1992 Dec; 176(6):1511-9. PubMed ID: 1460415 [TBL] [Abstract][Full Text] [Related]
5. Human lymphokine activated killer (LAK) cells suppress generation of allospecific cytotoxic T cells: implications for use of LAK cells to prevent graft-versus-host disease in allogeneic bone marrow transplantation. Uberti J; Martilotti F; Chou TH; Kaplan J Blood; 1992 Jan; 79(1):261-8. PubMed ID: 1370206 [TBL] [Abstract][Full Text] [Related]
6. Lymphokine-activated killer (LAK) cell anti-HIV-1 ADCC reactivity: a potential strategy for reduction of virus-infected cellular reservoirs. Tyler DS; Stanley SD; Bartlett JA; Bolognesi DP; Weinhold KJ J Surg Res; 1998 Oct; 79(2):115-20. PubMed ID: 9758725 [TBL] [Abstract][Full Text] [Related]
7. Interleukin-2-inducible natural immune (lymphokine-activated killer cell) responses as a functional correlate of progression to AIDS. Brenner BG; Gornitsky M; Wainberg MA Clin Diagn Lab Immunol; 1994 Sep; 1(5):538-44. PubMed ID: 8556498 [TBL] [Abstract][Full Text] [Related]
8. Different effects of breast cancer, HIV-1 infection and chemotherapy on inducible natural immunity. Brenner BG; Vo C; Wainberg MA Leukemia; 1994 Apr; 8 Suppl 1():S183-5. PubMed ID: 8152288 [TBL] [Abstract][Full Text] [Related]
9. Role of antibody-dependent cellular cytotoxicity and lymphokine-activated killer cells in AIDS and related diseases. Brenner BG; Gryllis C; Wainberg MA J Leukoc Biol; 1991 Dec; 50(6):628-40. PubMed ID: 1940615 [TBL] [Abstract][Full Text] [Related]
10. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing. Wiebke EA; Custer MC; Rosenberg SA; Lotze MT J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373 [TBL] [Abstract][Full Text] [Related]
11. Human cytotoxic effector cells: definition and analysis of activity. Ortaldo JR Allergol Immunopathol (Madr); 1991; 19(4):145-56. PubMed ID: 1726345 [TBL] [Abstract][Full Text] [Related]
12. Differential effects of chemotherapy-induced and HIV-1-induced immunocompromise on NK and LAK activities using breast cancer and HIV-1 seropositive patient populations. Brenner BG; Gryllis C; Gornitsky M; Cupples W; Wainberg M Anticancer Res; 1991; 11(2):969-74. PubMed ID: 2064353 [TBL] [Abstract][Full Text] [Related]
13. Induction of lymphokine-activated killer activity by interleukin 4 in human lymphocytes preactivated by interleukin 2 in vivo or in vitro. Higuchi CM; Thompson JA; Lindgren CG; Gillis S; Widmer MB; Kern DE; Fefer A Cancer Res; 1989 Dec; 49(23):6487-92. PubMed ID: 2479463 [TBL] [Abstract][Full Text] [Related]
14. Decreased lymphokine-activated killer cells in kidney transplant recipients. Correlation with a diminished number of CD3-/NKH1+ cells. Alard P; Lantz O; Ramirez A; Perrot JY; Chavanel G; Fries D; Charpentier B; Senik A Transplantation; 1990 Aug; 50(2):250-7. PubMed ID: 1696407 [TBL] [Abstract][Full Text] [Related]
15. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2. McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959 [TBL] [Abstract][Full Text] [Related]